J Cancer 2013; 4(5):402-415. doi:10.7150/jca.6780 This issue
1. Advanced Personalized Diagnostics LLC, 6006 Bangor Drive, Alexandria, VA 22303, USA.
2. Angiogenesis Core Facility, Advanced Technology Center, Room 115, Center for Cancer Research, National Cancer Institute, 8717 Grovemont Circle, Bethesda, MD 20892-4605, USA.
3. Tumor Growth Factor Section/Laboratory of Cancer Prevention, National Cancer Institute, Frederick, MD 21702-1201.
We have developed novel phenotypic fluorescent three-dimensional co-culture platforms that efficiently and economically screen anti-angiogenic/anti-metastatic drugs on a high-throughput scale. Individual cell populations can be identified and isolated for protein/gene expression profiling studies and cellular movement/interactions can be tracked by time-lapse cinematography. More importantly, these platforms closely parallel the in vivo angiogenic and metastatic outcomes of a given tumor xenograft in the nude mouse model but, unlike in vivo models, our co-culture platforms produce comparable results in five to nine days. Potentially, by incorporating cancer patient biopsies, the co-culture platforms should greatly improve the effectiveness and efficiency of personalized chemotherapy.
Keywords: Three-dimensional, Fluorescent, Angiogenesis, Metastasis, High-throughput, Drug screening, Personalized chemotherapy.